David Elmaleh

David ElmalehTitle: Chairman, Director, Chief Scientific Adviser

Company: FluoroPharma, Inc.

Location: Boston, MA

David R. Elmaleh, Ph.D. is the Chairman, Director and Chief Scientific Adviser of FluoroPharma, Inc., a a publicly traded company headquartered in Boston, which engages in the discovery, development and commercialization of proprietary medical diagnostic imaging products. Dr. Elmaleh specializes in radiopharmaceutical development and organic chemistry, and in his role, he manages business operations, oversees technology, and handles licensing processes and procedures. He is also responsible for developing compounds, and for designing clinical and preclinical studies. With more than 30 years of professional research and clinical experience, Dr. Elmaleh shines as a pioneer in the pharmaceuticals and biotechnology field; he is the developer of three pharmaceutical compounds that are currently being used in men or in late stage clinical trials. These compounds include the radiopharmaceutical preparation of (2FDG), which has been used in over a million PET imaging procedures, Beta-methyl modified fatty acid (BMIPP), a commercially successful cardiac SPECT agent in Japan, and Altropane, which has completed Phase III clinical trials. In addition to the role he performs at FlouroPharma, Inc., Dr. Elmaleh also serves as an Associate Professor of Radiology at Harvard Medical School.

Contact David Elmaleh

David Elmaleh

This entry was posted in Uncategorized. Bookmark the permalink.